11.07.2015 Views

Prescribed Drugs Provider Manual - Iowa Department of Human ...

Prescribed Drugs Provider Manual - Iowa Department of Human ...

Prescribed Drugs Provider Manual - Iowa Department of Human ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Iowa</strong><strong>Department</strong><strong>of</strong> <strong>Human</strong>Services<strong>Provider</strong> and Chapter<strong>Prescribed</strong> <strong>Drugs</strong>Chapter III. <strong>Provider</strong>-Specific PoliciesPage50DateAugust 1, 2013* Severe intolerance to vancomycin is defined as:• Severe rash, immune-complex-mediated, determined to be directlyrelated to vancomycin administration.• Red-man’s syndrome (histamine-mediated), refractory to traditionalcountermeasures (e.g., prolonged IV infusion, premedicated withdiphenhydramine).Use form 470-4275, Request for Prior Authorization: Linezolid (Zyvox ® ), torequest prior authorization. Click here to see a sample <strong>of</strong> the form.48. Mifepristone (Korlym ® )Prior authorization is required for mifepristone (Korlym ® ). Payment will beconsidered for patients when the following is met:♦ The patient is 18 years <strong>of</strong> age or older; and♦ Has a diagnosis <strong>of</strong> endogenous Cushing’s Syndrome with hyperglycemiasecondary to hypercortisolism in patients with Type 2 Diabetes or glucoseintolerance; and♦ Patient must have failure surgery or is not a candidate for surgery; and♦ Prescriber is an endocrinologist.♦ Female patients <strong>of</strong> reproductive age must have a negative pregnancy testconfirmed within the last seven days and must use a non-hormonalmethod <strong>of</strong> contraception during treatment and for one month afterstopping treatment.Use form 470-5141, Request for Prior Authorization: Mifepristone (Korlym ® ),to request prior authorization. Click here to see a sample <strong>of</strong> the form.49. Modified FormulationsPayment for a nonpreferred isomer, pro-drug, or metabolite will beconsidered when the following criteria are met:♦ Previous trial with a preferred parent drug <strong>of</strong> the same chemical entity ata therapeutic dose that resulted in a partial response with a documentedintolerance; and♦ Previous trial and therapy failure at a therapeutic dose with a preferreddrug <strong>of</strong> a different chemical entity indicated to treat the submitteddiagnosis if available.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!